The discipline of psychiatry has a plethora of guidelines, designed to serve the needs of the clinician. Yet, even a cursory glance is enough to discern the differences between the various guidelines. This paper reviews the current standard guidelines being followed across the world and proposes a unified guideline on the backbone of current evidence and practice being followed. The algorithm for pharmacological and psychosocial treatment for bipolar disorder, major depressive disorder, and schizophrenia is formulated after cross-comparison across four different guidelines and recent meta-analytical evidence. For every disorder, guidelines have different suggestions. Hence, based on the current status of evidence, algorithms have been combined to form a unified guideline for management. Clinical practice guidelines form the basis of standard clinical practice for all disciplines of medicine, including psychiatry. Yet, they are often not read or followed because of poor quality or because of barriers to implementation due to either lack of agreement or ambiguity. A unified guideline can go a long way in helping clear some of the confusion that has crept in due to the use of different guidelines across the world. 1. Introduction Standard clinical practice is considered the hallmark of every clinician, which is usually dictated by adhering to certain clinical guidelines [1]. A good guideline should be able to (a) identify the key decisions (e.g., diagnosis, assessment strategy, and treatment choice), (b) review the relevant, valid evidence on the benefits, risks, and costs of alternative decisions, and (c) present recommendations in a concise, updated format [1, 2]. Guidelines should use best evidence available as well as having the flexibility of being regularly updated, without leaving any scope for ambiguity. They have, therefore, the best potential for ensuring that rigorous clinical standards are maintained and “best practice” is followed by clinicians [2]. Yet, they are often not read or followed because of poor quality [3, 4] or because of barriers to implementation due to either lack of agreement or ambiguity [5]. This issue becomes even more important for trainee residents who are on their way to become consultants as they are required not only to adhere to guidelines while practicing, but also to be fully aware of them during their clinical evaluation. Psychiatry, as a discipline, is relatively new in the field of evidence based medicine; yet, there exist several clinical guidelines designed to provide guidance of good clinical practice. Some of
References
[1]
S. H. Woolf, “Practice guidelines, a new reality in medicine: II. Methods of developing guidelines,” Archives of Internal Medicine, vol. 152, no. 5, pp. 946–952, 1992.
[2]
R. Jackson and G. Feder, “Guidelines for clinical guidelines,” British Medical Journal, vol. 317, no. 7156, pp. 427–428, 1998.
[3]
P. Littlejohns, F. Cluzeau, R. Bale, J. Grimshaw, G. Feder, and S. Moran, “The quantity and quality of clinical practice guidelines for the management of depression in primary care in the UK,” British Journal of General Practice, vol. 49, no. 440, pp. 205–210, 1999.
[4]
T. M. Shaneyfelt, M. F. Mayo-Smith, and J. Rothwangl, “Are guidelines following guidelines?. The methodological quality of clinical practice guidelines in the peer-reviewed medical literature,” Journal of the American Medical Association, vol. 281, no. 20, pp. 1900–1905, 1999.
[5]
M. D. Cabana, C. S. Rand, N. R. Powe et al., “Why don't physicians follow clinical practice guidelines?: a framework for improvement,” Journal of the American Medical Association, vol. 282, no. 15, pp. 1458–1465, 1999.
[6]
Practice guideline 2006: American Psychiatric Association, http://www.psych.org/mainmenu/psychiatricpractice/practiceguidelines_1.aspx.
[7]
Canadian Psychiatric Association, “Clinical Practice Guidelines-for the treatment of depressive disorders,” Canadian Journal of Psychiatry, vol. 46, no. S1, pp. 1S–90S, 2001.
[8]
Canadian Psychiatric Association, “Clinical Practice Guidelines-treatment of schizophrenia,” Canadian Journal of Psychiatry, vol. 50, no. S1, pp. 1S–56S, 2005.
[9]
L. N. Yatham, S. H. Kennedy, C. O'Donovan et al., “Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patienst with bipolar disorder: consensus and controversies,” Bipolar Disorders, Supplement, vol. 7, no. 3, pp. 5–69, 2005.
[10]
L. N. Yatham, S. H. Kennedy, C. O'donovan et al., “Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007,” Bipolar Disorders, vol. 8, no. 6, pp. 721–739, 2006.
[11]
National Institute for Health & Clinical Excellence, “NICE guidelines for Mental Health & Behavioral conditions,” 2010, http://guidance.nice.org.uk/Topic/MentalHealthBehavioural.
[12]
D. Taylor, C. Paton, and S. Kapur, The Maudsley Prescribing Guidelines, Informa Healthcare, London, UK, 10th edition, 2009.
[13]
A. Cipriani, C. Barbui, G. Salanti et al., “Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis,” The Lancet, vol. 378, no. 9799, pp. 1306–1315, 2011.
[14]
G. S. Malhi, D. Adams, L. Lampe et al., “Clinical practice recommendations for bipolar disorder,” Acta Psychiatrica Scandinavica, vol. 119, no. s439, pp. 27–46, 2009.
[15]
M. A. Frye, “Bipolar disorder—a focus on depression,” The New England Journal of Medicine, vol. 364, no. 1, pp. 51–59, 2011.
[16]
A. M. A. Nivoli, F. Colom, A. Murru et al., “New treatment guidelines for acute bipolar depression: a systematic review,” Journal of Affective Disorders, vol. 129, no. 1–3, pp. 14–26, 2011.
[17]
M. L. Zupancic, “Role of atypical antipsychotics in rapid cycling bipolar disorder: a review of the literature,” Annals of Clinical Psychiatry, vol. 23, no. 2, pp. 141–149, 2011.
[18]
J. R. T. Davidson, “Major depressive disorder treatment guidelines in America and Europe,” The Journal of Clinical Psychiatry, vol. 71, no. E1, p. e04, 2010.
[19]
D. J. Nutt, J. R. T. Davidson, A. J. Gelenberg et al., “International consensus statement on major depressive disorder,” The Journal of Clinical Psychiatry, vol. 71, no. E1, p. e08, 2010.
[20]
G. S. Malhi, D. Adams, R. Porter et al., “Clinical practice recommendations for depression,” Acta Psychiatrica Scandinavica, vol. 119, no. 439, pp. 8–26, 2009.
[21]
J. M. Kane and C. U. Correll, “Pharmacologic treatment of schizophrenia,” Dialogues in Clinical Neuroscience, vol. 12, no. 3, pp. 345–357, 2010.
[22]
R. Tandon, R. H. Belmaker, W. F. Gattaz et al., “World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia,” Schizophrenia Research, vol. 100, no. 1–3, pp. 20–38, 2008.
[23]
J. Kreyenbuhl, R. W. Buchanan, F. B. Dickerson, and L. B. Dixon, “The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009,” Schizophrenia Bulletin, vol. 36, no. 1, pp. 94–103, 2010.
[24]
L. B. Dixon, F. Dickerson, A. S. Bellack et al., “The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements,” Schizophrenia Bulletin, vol. 36, no. 1, pp. 48–70, 2010.
[25]
D. A. Davis and A. Taylor-Vaisey, “Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines,” Canadian Medical Association Journal, vol. 157, no. 4, pp. 408–416, 1997.
[26]
R. S. A. Hayward, “Clinical practice guidelines on trial,” Canadian Medical Association Journal, vol. 156, no. 12, pp. 1725–1727, 1997.
[27]
L. I. Solberg, M. L. Brekke, C. J. Fazio et al., “Lessons from experienced guideline implementers: attend to many factors and use multiple strategies,” The Joint Commission Journal on Quality Improvement, vol. 26, no. 4, pp. 171–188, 2000.
[28]
L. Samalin, S. Guillaume, C. Auclair, and P.-M. Llorca, “Adherence to guidelines by french psychiatrists in their real world of clinical practice,” Journal of Nervous and Mental Disease, vol. 199, no. 4, pp. 239–243, 2011.
[29]
K. K. Milner and M. Valenstein, “A comparison of guidelines for the treatment of schizophrenia,” Psychiatric Services, vol. 53, no. 7, pp. 888–890, 2002.
[30]
W. Gaebel, S. Weinmann, N. Sartorius, W. Rutz, and J. S. McIntyre, “Schizophrenia practice guidelines: international survey and comparison,” British Journal of Psychiatry, vol. 187, pp. 248–255, 2005.
